Rockefeller Capital Management L.P. Argenx Se Transaction History

Rockefeller Capital Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	BUY	$342.17 - $402.31 $59,879 - $70,404	175 Added 406.98%	218 $80,000
Q3 2022 Nov 02, 2022	SELL	$343.2 - $395.75 $20,592 - $23,745	-60 Reduced 58.25%	43 $14,000
Q2 2022 Aug 12, 2022	BUY	$269.58 - $378.88 $15,905 - $22,353	59 Added 134.09%	103 $38,000
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $4,834 - $6,670	19 Added 76.0%	44 $13,000
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $2,176 - $2,824	8 Added 47.06%	25 $8,000
Q2 2021 Aug 10, 2021	SELL	$257.11 - $319.92 $514 - $639	-2 Reduced 10.53%	17 $5,000
Q1 2021 May 11, 2021	SELL	$268.3 - $380.31 $142,467 - $201,944	-531 Reduced 96.55%	19 $4,000
Q4 2020 Feb 12, 2021	SELL	$248.13 - $308.36 $22,083 - $27,444	-89 Reduced 13.93%	550 $161,000
Q3 2020 Nov 13, 2020	BUY	$215.51 - $272.51 $21,335 - $26,978	99 Added 18.33%	639 $167,000
Q2 2020 Aug 12, 2020	BUY	$127.44 - $232.72 $66,778 - $121,945	524 Added 3275.0%	540 $122,000
Q1 2020 May 12, 2020	BUY	$108.83 - $165.23 $1,741 - $2,643	16 New	16 $2,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.